FGFR1 (W666R)
Sign in to save this workspaceFGFR1 · Variant type: point · HGVS: p.W666R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Infigratinib | 99.0% | 1.0% | 98.24 |
| 2 | Futibatinib | 98.3% | 1.7% | 98.48 |
| 3 | Pemigatinib | 98.2% | 1.8% | 98.23 |
| 4 | Erdafitinib | 98.0% | 2.0% | 95.71 |
| 5 | Alpelisib | 97.9% | 2.1% | 97.22 |
| 6 | Ripretinib | 94.5% | 5.5% | 92.95 |
| 7 | Pralsetinib | 93.0% | 7.0% | 93.43 |
| 8 | Deucravacitinib | 91.0% | 9.0% | 98.99 |
| 9 | Tenalisib | 90.2% | 9.8% | 97.98 |
| 10 | Tivozanib | 89.1% | 10.9% | 92.42 |
| 11 | Selpercatinib | 83.0% | 17.0% | 96.72 |
| 12 | Entrectinib | 77.6% | 22.4% | 93.69 |
| 13 | Fedratinib | 73.3% | 26.7% | 96.21 |
| 14 | Repotrectinib | 72.9% | 27.1% | 84.21 |
| 15 | Pacritinib | 69.3% | 30.7% | 88.64 |
| 16 | Sunitinib | 59.2% | 40.8% | 91.73 |
| 17 | Sorafenib | 59.0% | 41.0% | 96.72 |
| 18 | Defactinib | 58.4% | 41.6% | 92.68 |
| 19 | Pirtobrutinib | 49.5% | 50.5% | 99.49 |
| 20 | Vandetanib | 49.3% | 50.7% | 95.74 |
| 21 | Upadacitinib | 46.0% | 54.0% | 97.98 |
| 22 | Apatinib | 44.4% | 55.6% | 97.73 |
| 23 | Tepotinib | 43.0% | 57.0% | 99.75 |
| 24 | Umbralisib | 29.0% | 71.0% | 98.74 |
| 25 | Pexidartinib | 24.2% | 75.8% | 99.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Infigratinib | 99.0% | 99.2% | -0.2% |
| Futibatinib | 98.3% | 99.0% | -0.7% |
| Pemigatinib | 98.2% | 99.9% | -1.7% |
| Erdafitinib | 98.0% | 99.0% | -1.0% |
| Alpelisib | 97.9% | 98.7% | -0.8% |
| Ripretinib | 94.5% | 86.5% | +8.0% |
| Pralsetinib | 93.0% | 93.2% | -0.2% |
| Deucravacitinib | 91.0% | 85.1% | +5.8% |
| Tenalisib | 90.2% | 93.2% | -3.0% |
| Tivozanib | 89.1% | — | — |
| Selpercatinib | 83.0% | 87.4% | -4.4% |
| Entrectinib | 77.6% | 76.8% | +0.8% |
| Fedratinib | 73.3% | 72.8% | +0.5% |
| Repotrectinib | 72.9% | — | — |
| Pacritinib | 69.3% | — | — |
| Sunitinib | 59.2% | — | — |
| Sorafenib | 59.0% | — | — |
| Defactinib | 58.4% | — | — |
| Pirtobrutinib | 49.5% | — | — |
| Vandetanib | 49.3% | 83.9% | -34.6% |
| Upadacitinib | 46.0% | — | — |
| Apatinib | 44.4% | — | — |
| Tepotinib | 43.0% | — | — |
| Umbralisib | 29.0% | — | — |
| Pexidartinib | 24.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_breast | Breast | ref |
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.5ms